(Z)-3-Hydroxy-2-(2-methoxy-pyrimidin-5-ylmethyl)-acrylic acid ethyl ester | 304693-85-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (Z)-3-Hydroxy-2-(2-methoxy-pyrimidin-5-ylmethyl)-acrylic acid ethyl ester
• CAS: 304693-85-4
• 化学式: C₁₁H₁₄N₂O₄
• 分子量: 238.243
• InChiKey: DKNSRWATVIOTDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.03
• 重原子数：
  17.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  81.54
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  (Z)-3-Hydroxy-2-(2-methoxy-pyrimidin-5-ylmethyl)-acrylic acid ethyl ester 在 sodium hydroxide 、 草酰氯 、 B-溴代邻苯二氧硼烷 、 potassium carbonate 、 N-乙基异丙基胺 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 2-[5-(1-Ethyl-2-oxo-1,2-dihydro-pyrimidin-5-ylmethyl)-2-(4-fluoro-benzylsulfanyl)-4-oxo-4H-pyrimidin-1-yl]-N-methyl-N-octyl-acetamide
  参考文献：
  名称：

  The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2

  摘要：

  Modification of the pyrimidone 5-substituent in a series of 1-((amidolinked)-alkyl)-pyrimidones, lipophilic inhibitors of lipoprotein-associated phospholipase A(2), has given inhibitors of nanomolar potency and improved physicochemical properties. Compound 23 was identified as a potent, highly water soluble, CNS penetrant inhibitor suitable for intravenous administration. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00038-5
• 作为产物：
  描述：

  ethyl 3-(2-methoxypyrimidin-5-yl)acrylate 在 palladium on activated charcoal 氢气 、 sodium hydride 、 三乙胺 作用下， 以 乙二醇二甲醚 、 乙醇 为溶剂， 生成 (Z)-3-Hydroxy-2-(2-methoxy-pyrimidin-5-ylmethyl)-acrylic acid ethyl ester
  参考文献：
  名称：

  The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2

  摘要：

  Modification of the pyrimidone 5-substituent in a series of 1-((amidolinked)-alkyl)-pyrimidones, lipophilic inhibitors of lipoprotein-associated phospholipase A(2), has given inhibitors of nanomolar potency and improved physicochemical properties. Compound 23 was identified as a potent, highly water soluble, CNS penetrant inhibitor suitable for intravenous administration. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00038-5

文献信息

• PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2
  申请人：Jin Yun

  公开号：US20130252963A1

  公开（公告）日：2013-09-26

  The present invention relates to novel compounds that inhibit Lp-PLA 2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA 2 , or example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

  本发明涉及一种新的化合物，其抑制Lp-PLA2活性，其制备过程，包含它们的组合物以及它们在治疗与Lp-PLA2活性相关的疾病中的应用，例如动脉粥样硬化，阿尔茨海默病和/或糖尿病黄斑水肿。